Jade Biosciences, Inc. cash flow to debt ratio of -13.08K% indicates that the company cannot generate enough cash to cover its debt over time. This level indicates weak financial health.

Jade Biosciences, Inc.'s free cash flow has decreased 33.27% from $-71.20M last year to $-94.89M, signaling decreasing performance

Jade Biosciences, Inc.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Jade Biosciences, Inc.'s debt has decreased relative to shareholder equity from 0.01 last year to 0.00 today, signaling strengthened financials

Jade Biosciences, Inc. has a net cash position, so leverage is healthy.

Jade Biosciences, Inc. earns at least as much interest as it pays. Interest obligations are fully covered.

Jade Biosciences, Inc. has insufficient data to evaluate this check.

Jade Biosciences, Inc.'s short-term assets of $336.16M exceed its short-term liabilities of $16.54M

Jade Biosciences, Inc.'s return on assets of 0.00% is lower than the 5.00% threshold, indicating inefficient asset utilization

Jade Biosciences, Inc.'s return on equity of -49.11%, is lower than 15.00%, indicating bad performance

Jade Biosciences, Inc.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Jade Biosciences, Inc. had positive net income in only 0 out of 5 years, indicating unstable earnings

Jade Biosciences, Inc. has negative free cash flow, indicating the company is burning cash rather than generating it

Jade Biosciences, Inc. has negative free cash flow, indicating cash burn

Jade Biosciences, Inc.'s yearly earnings has decreased 82.99% since last year from $-69.63M to $-127.41M, signaling decreasing performance

Jade Biosciences, Inc.'s yearly revenue has increased 0.00% since last year from $0.00 to $0.00, signaling increasing performance

ROIC -37.39% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Jade Biosciences, Inc. has insufficient revenue history to calculate 3-year revenue CAGR.

Jade Biosciences, Inc. had revenue growth in 5 out of 5 years, indicating consistent revenue performance

Jade Biosciences, Inc. had positive ROE in only 0 out of 5 years, indicating inconsistent returns on equity

Jade Biosciences, Inc. has insufficient data to evaluate this check.

Jade Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jade Biosciences, Inc. is overvalued relative to its fair value price of 0.00 based on EBITDA multiple model

Jade Biosciences, Inc. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Jade Biosciences, Inc. has insufficient data to evaluate this check.

Jade Biosciences, Inc. has negative trailing-twelve-month earnings; this ratio is not meaningful and the check fails

Jade Biosciences, Inc. has a price-to-book ratio of 3.02x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Jade Biosciences, Inc. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue